Journal
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
Volume 9, Issue 12, Pages 1471-1481Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2015.1096774
Keywords
5-fluorouracil; adjuvant; capecitabine; chemotherapy; gastric cancer; palliative
Categories
Funding
- F Hoffmann La-Roche Ltd.
Ask authors/readers for more resources
Capecitabine is an orally administered prodrug of 5-fluorouracil (5-FU) and was designed to specifically affect tumor cells more than normal tissues. Capecitabine is as effective and well tolerated as infusional 5-FU in the treatment of advanced gastric cancer (AGC). Following the REAL-2 and ML17032 studies, capecitabine has replaced infusional 5-FU for treating GC. Capecitabine plus platinum is one of the most widely used regimens for the first-line treatment of AGC, regardless of HER2 status. The adjuvant capecitabine/oxaliplatin regimen is one therapeutic option for resectable gastric cancer, especially after D2 resection. Compared with S-1, capecitabine has been shown to have a similar efficacy, but is associated with fewer ethnic differences than S-1, which accounts for the more widespread usage of capecitabine worldwide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available